You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Economist discusses the effect of the COVID-19 pandemic on how scientific research is communicated.
Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.
The firm recently published a paper with its sibling company HiFiBio on antibody sequencing, but is looking to develop more applications.
A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.
The firm's single-cell T cell receptor profiling method was published this month as part of a study to develop reusable antigen reactivity screens.
The method uses nanopore sequencing to analyze short cell-free DNA fragments from blood, providing results in as little as six hours.
All three methods build on the use of methyltransferases to mark accessible regions of the genome, using nanopore sequencing to detect the modifications.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The study, led by NYU researchers, provides a mathematical framework to find gene sets identifiable via both methods, revealing tissue architecture.
The New York Times reports academic researchers often work right through the holidays and over the weekends.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.